Vancomycin nephrotoxicity: A review

Journal of Pharmacy Practice

Volumn 27, Issue 6, 2014, Pages 545-553

  Mergenhagen, Kari A ^a   Borton, Angela R ^b  

^a VA WESTERN NEW YORK HEALTHCARE SYSTEM   (United States)

^b ERIE COUNTY MEDICAL CENTER   (United States)

Author keywords

nephrotoxicity; therapeutic drug monitoring; vancomycin

Indexed keywords

AMINOGLYCOSIDE; AMPHOTERICIN B; AMRINONE; ANGIOTENSIN RECEPTOR ANTAGONIST; CILASTATIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ERDOSTEINE; ERYTHROPOIETIN; GINKGO BILOBA EXTRACT; LINEZOLID; MALATE DEHYDROGENASE; MELATONIN; NONSTEROID ANTIINFLAMMATORY AGENT; TACROLIMUS; VANCOMYCIN; ANTIINFECTIVE AGENT;

ACUTE KIDNEY FAILURE; ARTICLE; CHRONIC KIDNEY DISEASE; CONTROLLED CLINICAL TRIAL (TOPIC); DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG MONITORING; GLOMERULUS FILTRATION RATE; HEALTH CARE COST; HUMAN; HYPOTENSION; KIDNEY DYSFUNCTION; KIDNEY PROXIMAL TUBULE; KIDNEY TUBULE NECROSIS; LENGTH OF STAY; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; MORBIDITY; MULTICENTER STUDY (TOPIC); NEPHROTOXICITY; NONHUMAN; OBESITY; OXIDATIVE STRESS; RISK ASSESSMENT; RISK FACTOR; TREATMENT DURATION; CHEMICALLY INDUCED; KIDNEY DISEASE;

ANTI-BACTERIAL AGENTS; HUMANS; KIDNEY DISEASES; RISK FACTORS; VANCOMYCIN;

EID: 84910050724     PISSN: 08971900     EISSN: 15311937     Source Type: Journal    
DOI: 10.1177/0897190014546114     Document Type: Article

References (39)

1. Levine DP. Vancomycin: a history. Clin Infect Dis. 2006 ; 42 (suppl 1). S5 - S12
2. Hazlewood KA, Brouse SD, Pitcher WD, et al. Vancomycin-associated nephrotoxicity: grave concern or death by character assassination?. Am J Med. 2010 ; 123 (2). 182.e181 - e187
3. Moellering RC. Vancomycin: a 50-year reassessment. Clin Infect Dis. 2006 ; 42 (suppl 1). S3 - S4
4. Rybak M, Lomaestro B, Rotschafer JC, et al. Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. Am J Health Syst Pharm. 2009 ; 66 (1). 82-98
5. Bergman MM, Glew RH, Ebert TH. Acute interstitial nephritis associated with vancomycin therapy. Arch Intern Med. 1988 ; 148 (10). 2139-2140
6. Codding CE, Ramseyer L, Allon M, et al. Tubulointerstitial nephritis due to vancomycin. Am J Kidney Dis. 1989 ; 14 (6). 512-515
7. Hidayat LK, Hsu DI, Quist R, et al. High-dose vancomycin therapy for methicillin-resistant Staphylococcus aureus infections: efficacy and toxicity. Arch Intern Med. 2006 ; 166 (19). 2138-2144
8. Cosgrove SE, Sakoulas G, Perencevich EN, et al. Comparison of mortality associated with methicillin-resistant and methicillin-susceptible Staphylococcus aureus bacteremia: a meta-analysis. Clin Infect Dis. 2003 ; 36 (1). 53-59
9. Chang S, Sievert DM, Hageman JC, et al. Infection with vancomycin-resistant Staphylococcus aureus containing the vanA resistance gene. N Engl J Med. 2003 ; 348 (14). 1342-1347
10. Tenover FC, Moellering RC. The rationale for revising the Clinical and Laboratory Standards Institute vancomycin minimal inhibitory concentration interpretive criteria for Staphylococcus aureus. Clin Infect Dis. 2007 ; 44 (9). 1208-1215
11. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med. 2005 ; 171 (4). 388-416
12. Performance Standards for Antimicrobial Susceptibility Testing: 16th Informational Supplement. Wayne, PA: Clinical and Laboratory Standards Institute ; 2006 :
13. Pritchard L, Baker C, Leggett J, et al. Increasing vancomycin serum trough concentrations and incidence of nephrotoxicity. Am J Med. 2010 ; 123 (12). 1143-1149
14. Bellomo R, Ronco C, Kellum JA, et al. Acute renal failure - definition, outcome measures, animal models, fluid therapy and information technology needs: the second international consensus conference of the acute dialysis quality initiative (ADQI) group. Crit Care (London, England). 2004 ; 8 (4). R204 - R212
15. Shen WC, Chiang YC, Chen HY, et al. Nephrotoxicity of vancomycin in patients with methicillin-resistant Staphylococcus aureus bacteraemia. Nephrology. 2011 ; 16 (8). 697-703
16. Mehta RL, Kellum JA, Shah SV, et al. Acute kidney injury network: report of an initiative to improve outcomes in acute kidney injury. Crit Care. 2007 ; 11 (2). R31
17. Minejima E, Choi J, Beringer P, et al. Applying new diagnostic criteria for acute kidney injury to facilitate early identification of nephrotoxicity in vancomycin-treated patients. Antimicrob Agents Chemother. 2011 ; 55 (7). 3278-3283
18. Bosso JA, Nappi J, Rudisill C, et al. Relationship between vancomycin trough concentrations and nephrotoxicity: a prospective multicenter trial. Antimicrob Agents Chemother. 2011 ; 55 (12). 5475-5479
19. Horey A, Mergenhagen KA, Mattappallil A. The relationship of nephrotoxicity to vancomycin trough serum concentrations in a veteran's population: a retrospective analysis. Ann Pharmacother. 2012 ; 46 (11). 1477-1483
20. Kullar R, Davis SL, Taylor TN, et al. Effects of targeting higher vancomycin trough levels on clinical outcomes and costs in a matched patient cohort. Pharmacotherapy. 2012 ; 32 (3). 195-201
21. Lodise TP, Lomaestro B, Graves J, et al. Larger vancomycin doses (at least four grams per day) are associated with an increased incidence of nephrotoxicity. Antimicrob Agents Chemother. 2008 ; 52 (4). 1330-1336
22. Lodise TP, Patel N, Lomaestro BM, et al. Relationship between initial vancomycin concentration-time profile and nephrotoxicity among hospitalized patients. Clin Infect Diseas. 2009 ; 49 (4). 507-514
23. Malacarne P, Bergamasco S, Donadio C. Nephrotoxicity due to combination antibiotic therapy with vancomycin and aminoglycosides in septic critically ill patients. Chemotherapy. 2006 ; 52 (4). 178-184
24. Wunderink RG, Niederman MS, Kollef MH, et al. Linezolid in methicillin-resistant Staphylococcus aureus nosocomial pneumonia: a randomized, controlled study. Clin Infect Dis. 2012 ; 54 (5). 621-629
25. Rybak MJ, Albrecht LM, Boike SC, et al. Nephrotoxicity of vancomycin, alone and with an aminoglycoside. J Antimicrob Chemother. 1990 ; 25 (4). 679-687
26. Jeffres MN, Isakow W, Doherty JA, et al. A retrospective analysis of possible renal toxicity associated with vancomycin in patients with health care-associated methicillin-resistant Staphylococcus aureus pneumonia. Clin Ther. 2007 ; 29 (6). 1107-1115
27. Toyoguchi T, Takahashi S, Hosoya J, et al. Nephrotoxicity of vancomycin and drug interaction study with cilastatin in rabbits. Antimicrobial Agents Chemother. 1997 ; 41 (9). 1985-1990
28. Cetin H, Olgar S, Oktem F, et al. Novel evidence suggesting an anti-oxidant property for erythropoietin on vancomycin-induced nephrotoxicity in a rat model. Clin Exp Pharmacol Physiol. 2007 ; 34 (11). 1181-1185
29. Oktem F, Arslan MK, Ozguner F, et al. In vivo evidences suggesting the role of oxidative stress in pathogenesis of vancomycin-induced nephrotoxicity: protection by erdosteine. Toxicology. 2005 ; 215 (3). 227-233
30. King DW, Smith MA. Proliferative responses observed following vancomycin treatment in renal proximal tubule epithelial cells. Toxicol In Vitro. 2004 ; 18 (6). 797-803
31. Celik I, Cihangiroglu M, Ilhan N, et al. Protective effects of different antioxidants and amrinone on vancomycin-induced nephrotoxicity. Basic Clin Pharmacol Toxicol. 2005 ; 97 (5). 325-332
32. Marre R, Schulz E, Anders T, et al. Renal tolerance and pharmacokinetics of vancomycin in rats. J Antimicrob Chemother. 1984 ; 14 (3). 253-260
33. Cimino MA, Rotstein C, Slaughter RL, et al. Relationship of serum antibiotic concentrations to nephrotoxicity in cancer patients receiving concurrent aminoglycoside and vancomycin therapy. Am J Med. 1987 ; 83 (6). 1091-1097
34. Fernandez de Gatta MD, Calvo MV, Hernandez JM, et al. Cost-effectiveness analysis of serum vancomycin concentration monitoring in patients with hematologic malignancies. Clin Pharmacol Ther. 1996 ; 60 (3). 332-340
35. Stevens LA, Schmid CH, Greene T, et al. Comparative performance of the CKD Epidemiology Collaboration (CKD-EPI) and the Modification of Diet in Renal Disease (MDRD) Study equations for estimating GFR levels above 60 mL/min/1.73 m2. Am J Kidney Dis. 2010 ; 56 (3). 486-495
36. Coca SG, Yusuf B, Shlipak MG, et al. Long-term risk of mortality and other adverse outcomes after acute kidney injury: a systematic review and meta-analysis. Am J Kidney Dis. 2009 ; 53 (6). 961-973
37. Darko W, Medicis JJ, Smith A, et al. Mississippi mud no more: cost-effectiveness of pharmacokinetic dosage adjustment of vancomycin to prevent nephrotoxicity. Pharmacotherapy. 2003 ; 23 (5). 643-650
38. Ye ZK, Tang HL, Zhai SD. Benefits of therapeutic drug monitoring of vancomycin: a systematic review and meta-analysis. PLoS One. 2013 ; 8 (10). e77169
39. Gupta A, Biyani M, Khaira A. Vancomycin nephrotoxicity: myths and facts. Neth J Med. 2011 ; 69 (9). 379-383